Main Article Content
Abstract
Keywords
Article Details
Information about financing and conflict of interests
The authors declare that they have no apparent or potential conflicts of interest related to the publication of this article.
This work is licensed under a Creative Commons Attribution 4.0 License.
How to Cite
References
Klimtchuk ES, Prokaeva T, Frame NM, Abdullahi HA, Spencer B, Dasari S, et al. Unusual duplica- tion mutation in a surface loop of human transthyretin leads to an aggressive drug-resistant amyloid disease. Proc Natl Acad Sci USA. 2018; 115: E6428-E6436. doi: 10.1073/pnas.1802977115
Koike H, Katsuno M. Ultrastructure in transthyretin amyloid- osis: from pathophysiology to therapeutic insights. Biomedicines. 2019; 7(1): 11. doi: 10.3390/biomedicines7010011
Mangione PP, Verona G, Corazza A, Marcoux J, Canetti D, Giorgetti S, et al. Plasminogen activa- tion triggers transthyretin amyloidogenesis in vitro. J Biol Chem. 2018; 293(37): 14192-14199. doi: 10.1074/jbc.RA118.003990
Adams D, Suhr OB, Hund E, Obici L, Tournev I, Campistol JM, et al. First European consensus for diagnosis, management, and treatment of transthyretin familial amyloid polyneuropathy. Curr Opin Neurol. 2016; 29(Suppl. 1): S14-26. doi: 10.1097/WCO.0000000000000289
Gertz MA. Hereditary ATTR amyloidosis: burden of illness and diagnostic challenges. Am J Manag Care. 2017; 23(7 Suppl): S107-S112
Naumova ES, Nikitin SS, Adyan TA, Druzhinin DS, Varshavskiy VA. Misdiagnosed case of transthyretin amyloidosis in a fully investigated patient. Neuromuscular Diseases. 2018; 8(1): 46-52. Russian (Наумова Е.С., Никитин С.С., Адян Т.А., Дружинин Д.С., Варшавский В.А. Клинический случай транстиретинового амилоидоза с задержкой верификации диагноза у полностью обследованной больной //Нервно-мышечные болезни. 2018. Т. 8, № 1. С. 42-56.) doi: 10.17650/2222-8721-2018-8-1-46-52
Adams D, Gonzalez-Duarte A, O’Riordan WD, Yang Ch-Ch, Ueda M, Kristen AV, et al. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. N Engl J Med. 2018; 379(1): 11-21. doi: 10.1056/NEJMoa1716153
Rameev VV. Recent methods of diagnosis and treatment of hereditary transthyretin amyloidosis. Manage pain. 2018; 1: 20-24. Russian (Рамеев В.В. Современные методы диагностики и лечения транстиретинового наследственного амилоидоза //Manage pain. 2018. № 1. С. 20-24)
Ruger J, Ioannou S, Castanotto D, Stein CA. Oligonucleotides to the (Gene) Rescue: FDA Approvals 2017-2019. Trends Pharmacol Sci. 2020; 41(1): 27-41. doi: 10.1016/j.tips.2019.10.009
Gales L. Tegsedi (Inotersen): An antisense oligonucleotide approved for the treatment of adult patients with hereditary transthyretin amyloidosis. Pharmaceuticals (Basel). 2019; 12(2): 78. doi: 10.3390/ph1202007810.3390/ph12020078